10 results about "Anaphylactoid reactions" patented technology

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The invention discloses a luminescent cell for rapidly detecting drug allergy and / or anaphylactoid reaction as well as a construction method and application of the luminescent cell, and relates to the technical field of biology. The construction method comprises the following steps: transforming myeloid related cells by using a recombinant vector containing a marker gene and an HHEXA gene promoter to obtain recombinant cells; the recombinant cell is the luminescent cell. According to the invention, the HHEXA gene promoter and the marker gene are recombined and then transferred into myeloid related cells, and the occurrence of the allergy or anaphylactoid reaction can be intuitively reflected through a marker signal by utilizing the specific activation characteristic of the HHEXA gene in the allergy / anaphylactoid reaction. The luminescent cell has good stability, is suitable for multiple scenes such as drug allergy, anaphylactoid risk assessment, environmental sample analysis and the like, provides an efficient, sensitive and convenient technical tool for clinical rapid diagnosis, new drug research and development and scientific research and exploration, and can significantly reduce the detection cost and the operation threshold.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

According to the present invention, the immobilized human serum albumin HSA is adopted as the affinity screening medium, and the UHPLC-MS / MS analysis and molecular docking verification method is combined so as to rapidly identify the chemical components having the human serum albumin binding activity and the potential sensitization in the safflower injection. The screening and verification technology disclosed by the invention discovers and confirms that 6-hydroxykaempferol-3, 6, 7-tri-O-glucoside in the safflower injection is a main suspected anaphylactoid substance for the first time; a corresponding detection method, a removal process and a standardized detection kit are further established, and a system closed loop from sensitizing substance screening and quantitative detection to production process control is realized. The method not only overcomes the limitation that allergy risk components cannot be accurately identified and quantified in the prior art, but also provides reliable technical support for prevention and control of anaphylactoid reactions of traditional Chinese medicine injections.

Disclosed are a urea compound containing nitrobenzene, a preparation method therefor, and use thereof. The preparation method comprises: dissolving bis(trichloromethyl)carbonate in anhydrous tetrahydrofuran, adding a solution of 4-nitroaniline in tetrahydrofuran, stirring uniformly after dropwise addition is completed, then adding triethylamine, stirring uniformly, evaporating the solvent to dryness, adding a solution of 4-aminobenzotrifluoride in anhydrous tetrahydrofuran, and reacting at 45 °C for 3 h to obtain the urea compound containing nitrobenzene. The urea compound containing nitrobenzene can effectively alleviate the swelling and plasma extravasation of the soles of mice, and skin vasodilation and mast cell degranulation of the soles of mice, which are caused by C48 / 80, thereby inhibiting the occurrence of anaphylactoid reactions. Therefore, using the urea compound containing nitrobenzene as an anti-drug allergy formulation provides more possible treatment regimens for the clinical treatment of drug allergies.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The application discloses a luminescent cell for rapidly detecting drug allergy and / or allergic reaction, and a construction method and application thereof, and relates to the technical field of biotechnology.The construction method comprises the following steps: transforming a myeloid-related cell with a recombinant vector containing a marker gene and an H_HEXA gene promoter to obtain a recombinant cell; and the recombinant cell is the luminescent cell.The application is characterized in that the H_HEXA gene promoter is recombined with the marker gene, and then is transformed into the myeloid-related cell, and the specific activation characteristics of the H_HEXA gene in the allergic reaction / allergic reaction are utilized, so that the occurrence of the allergic reaction or the allergic reaction can be directly reflected through a marker signal.The luminescent cell has good stability, is suitable for drug allergy, allergic reaction risk assessment, environmental sample analysis and other scenes, and provides an efficient, sensitive and convenient technical tool for clinical rapid diagnosis, new drug research and development and scientific research exploration, and can significantly reduce detection cost and operation threshold.